Article
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
JAMA - 17 Mar 2015
Nan Hongmei, Hutter Carolyn M, Lin Yi, Jacobs Eric J, Ulrich Cornelia M, White Emily, Baron John A, Berndt Sonja I, Brenner Hermann, Butterbach Katja, Caan Bette J, Campbell Peter T, Carlson Christopher S, Casey Graham, Chang-Claude Jenny, Chanock Stephen J, Cotterchio Michelle, Duggan David, Figueiredo Jane C, Fuchs Charles S, Giovannucci Edward L, Gong Jian, Haile Robert W, Harrison Tabitha A, Hayes Richard B, Hoffmeister Michael, Hopper John L, Hudson Thomas J, Jenkins Mark A, Jiao Shuo, Lindor Noralane M, Lemire Mathieu, Le Marchand Loic, Newcomb Polly A, Ogino Shuji, Pflugeisen Bethann M, Potter John D, Qu Conghui, Rosse Stephanie A, Rudolph Anja, Schoen Robert E, Schumacher Fredrick R, Seminara Daniela, Slattery Martha L, Thibodeau Stephen N, Thomas Fridtjof, Thornquist Mark, Warnick Greg S, Zanke Brent W, Gauderman W James, Peters Ulrike, Hsu Li, Chan Andrew T
Abstract excerpt
IMPORTANCE: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer. OBJECTIVE: To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.